The Nuclear Medicine Market is a strategically important segment within the global diagnostic imaging and targeted therapy landscape, centered on the use of radiopharmaceuticals for disease detection, functional assessment, treatment planning, and increasingly, precision-guided therapy. Nuclear medicine plays a critical role across oncology, cardiology, neurology, endocrinology, and selected inflammatory and metabolic disorders, with its top applications spanning PET and SPECT imaging, hybrid modalities such as PET/CT and SPECT/CT, thyroid-related procedures, and a growing range of radiopharmaceutical therapies. The principal end-use settings include hospitals, specialty imaging centers, academic medical institutions, oncology networks, and nuclear pharmacies supporting time-sensitive preparation and distribution. Recent market trends highlight the continued rise of theranostics, where paired diagnostic and therapeutic radiopharmaceuticals are used to identify and treat specific disease targets, alongside the broader clinical adoption of hybrid imaging systems that combine anatomical and functional information. The market is also benefiting from expanding use of molecular imaging in oncology care pathways, deeper interest in radioligand therapy, and stronger alignment with precision medicine approaches.

The Transthyretin Amyloidosis Market is evolving from a narrowly treated rare-disease segment into a more structured, multi-modality specialty market as awareness, diagnosis, and disease-modifying treatment options expand. Transthyretin amyloidosis spans two major clinical demand pools—cardiomyopathy and polyneuropathy—with treatment adoption increasingly shaped by earlier detection, subtype differentiation, and the shift toward intervention before irreversible organ damage. The market’s top end uses are centered on hospital-based cardiology, neurology, rare disease centers, and multidisciplinary referral networks, where therapy decisions increasingly depend on genotype status, disease stage, cardiac involvement, neurologic burden, and long-term tolerability. Current momentum is being reinforced by broader recognition of red-flag symptoms, higher use of non-invasive imaging pathways, and more systematic genetic confirmation in diagnosed patients.